Cancer immunoediting from immune surveillance to immune escape

Cancer immune surveillance is considered to be an important host protection process to inhibit carcinogenesis and to maintain cellular homeostasis. In the interaction of host and tumour cells, three essential phases have been proposed: elimination, equilibrium and escape, which are designated the ‘three E’s'. Several immune effector cells and secreted cytokines play a critical role in pursuing each process. Nascent transformed cells can initially be eliminated by an innate immune response such as by natural killer cells. During tumour progression, even though an adaptive immune response can be provoked by antigen‐specific T cells, immune selection produces tumour cell variants that lose major histocompatibility complex class I and II antigens and decreases amounts of tumour antigens in the equilibrium phase. Furthermore, tumour‐derived soluble factors facilitate the escape from immune attack, allowing progression and metastasis. In this review, the central roles of effector cells and cytokines in tumour immunity, and the escape mechanisms of tumour cells during tumour progression are discussed.

[1]  K. Arihiro,et al.  Tumor-driven evolution of immunosuppressive networks during malignant progression. , 2006, Cancer research.

[2]  M. Karin Nuclear factor-κB in cancer development and progression , 2006, Nature.

[3]  T. Tomasi,et al.  Epigenetic regulation of immune escape genes in cancer , 2006, Cancer Immunology, Immunotherapy.

[4]  H. Salih,et al.  Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA , 2006, Cancer Immunology, Immunotherapy.

[5]  R. Zarbo,et al.  Use of microsatellite analysis in detection of tumor lineage as a cause of death in a liver transplant patient. , 2006, Archives of pathology & laboratory medicine.

[6]  G. Trinchieri,et al.  Dendritic cell-NK cell cross-talk: regulation and physiopathology. , 2006, Current topics in microbiology and immunology.

[7]  M. Karin Nuclear factor-kappaB in cancer development and progression. , 2006, Nature.

[8]  C. Mignogna,et al.  Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior? , 2006, International journal of immunopathology and pharmacology.

[9]  E. Bloemena,et al.  Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients , 2006, Cancer Immunology, Immunotherapy.

[10]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Sinha,et al.  Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. , 2005, Cancer research.

[12]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[13]  B. Chauffert,et al.  Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4+CD25+ regulatory T cell proliferation , 2005, The Journal of experimental medicine.

[14]  H. Dressman,et al.  Gene Expression Changes and Signaling Events Associated with the Direct Antimelanoma Effect of IFN-γ , 2005 .

[15]  M. Kloor,et al.  Transmission of donor-derived small-cell carcinoma cells by a nontumor-bearing allograft. , 2005, Transplantation.

[16]  G. Semenza,et al.  Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways , 2005, Oncogene.

[17]  G. Klein,et al.  Surveillance against tumors--is it mainly immunological? , 2005, Immunology letters.

[18]  R. Schreiber,et al.  A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.

[19]  K. Tanabe,et al.  Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses , 2005, Cancer biology & therapy.

[20]  T. Soussi,et al.  p53 mutation heterogeneity in cancer. , 2005, Biochemical and biophysical research communications.

[21]  G. Parmiani,et al.  Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. , 2005, Gastroenterology.

[22]  L. de Leval,et al.  Transmission of an undiagnosed sarcoma to recipients of kidney and liver grafts procured in a non‐heart beating donor , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[23]  P. Sinha,et al.  Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression , 2005, Cancer Immunology, Immunotherapy.

[24]  T. Iwakuma,et al.  Li-Fraumeni Syndrome: a p53 Family Affair , 2005, Cell cycle.

[25]  T. Lehnert,et al.  Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease , 2005, Gut.

[26]  M. Mandal,et al.  Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788 , 2005, Molecular Cancer Therapeutics.

[27]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[28]  Simon C Watkins,et al.  Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  G. Trinchieri,et al.  Production of type I interferons: plasmacytoid dendritic cells and beyond , 2005 .

[30]  B. Erdoğan,et al.  The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients. , 2005, Tuberkuloz ve toraks.

[31]  H. Dressman,et al.  Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma. , 2005, Cancer research.

[32]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[33]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[34]  D. Meek,et al.  The p53 response to DNA damage. , 2004, DNA repair.

[35]  K. Tanabe,et al.  The role of Fas ligand and transforming growth factor β in tumor progression , 2004 .

[36]  H. Goldschmidt,et al.  Malignancy in renal transplantation. , 2004, Journal of the American Society of Nephrology : JASN.

[37]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[38]  M. Smyth,et al.  Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells , 2004, The Journal of experimental medicine.

[39]  D. Amadori,et al.  Immunosuppression in Renal Cancer: Differential Expression of Signal Transduction Molecules in Tumor-Infiltrating, Near-Tumor Tissue, and Peripheral Blood Lymphocytes , 2004, Cancer investigation.

[40]  K. Malmberg Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? , 2004, Cancer immunology, immunotherapy : CII.

[41]  K. Tanabe,et al.  The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. , 2004, Cancer.

[42]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[43]  M. Doubrovin,et al.  Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma 1 , 2003, The Journal of Immunology.

[44]  James E. Evans,et al.  Molecular identification of a danger signal that alerts the immune system to dying cells , 2003, Nature.

[45]  R. Dummer,et al.  HLA-G and IL-10 expression in human cancer--different stories with the same message. , 2003, Seminars in cancer biology.

[46]  M. Miyazaki,et al.  Preoperative Natural Killer Cell Activity as a Prognostic Factor for Distant Metastasis following Surgery for Colon Cancer , 2003, Digestive Surgery.

[47]  G. Forni,et al.  α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[48]  H. Pircher,et al.  A Critical Requirement of Interferon γ-mediated Angiostasis for Tumor Rejection by CD8+ T Cells , 2003 .

[49]  F. Balkwill,et al.  IFN-γ Induces Apoptosis in Ovarian Cancer Cells in Vivo and in Vitro , 2003 .

[50]  H. Joensuu,et al.  Elevated serum endostatin is associated with poor outcome in patients with non‐Hodgkin lymphoma , 2003, Cancer.

[51]  H. Groux,et al.  Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. , 2003, Immunity.

[52]  Austin C. Stonebraker,et al.  Presentation of Antigen by Endothelial Cells and Chemoattraction Are Required for Homing of Insulin-specific CD8+ T Cells , 2003, The Journal of experimental medicine.

[53]  R. MacKie,et al.  Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. , 2003, The New England journal of medicine.

[54]  J. Shabanowitz,et al.  Hsp90 binds CpG oligonucleotides directly: implications for Hsp90 as a missing link in CpG signaling and recognition , 2003, Cellular and Molecular Life Sciences CMLS.

[55]  F. Balkwill,et al.  IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  H. Pircher,et al.  A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. , 2003, Cancer research.

[57]  M. Nishimura,et al.  Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. , 2002, Immunity.

[58]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[59]  C. Yee,et al.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.

[60]  A. Enk,et al.  Immature, but not inactive: the tolerogenic function of immature dendritic cells , 2002, Immunology and cell biology.

[61]  S. Akira,et al.  Differential involvement of IFN-beta in Toll-like receptor-stimulated dendritic cell activation. , 2002, International immunology.

[62]  D. Keskin,et al.  Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase , 2002, Science.

[63]  J. Sherratt,et al.  Cells behaving badly: a theoretical model for the Fas/FasL system in tumour immunology. , 2002, Mathematical biosciences.

[64]  W. Marks,et al.  Transplant tumor registry: donor related malignancies , 2002, Transplantation.

[65]  J. Trapani,et al.  Suppression of Lymphoma and Epithelial Malignancies Effected by Interferon γ , 2002, The Journal of experimental medicine.

[66]  Lloyd J. Old,et al.  The roles of IFNγ in protection against tumor development and cancer immunoediting , 2002 .

[67]  K. Hiroshima,et al.  Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. , 2002, Lung cancer.

[68]  Hiroaki Ikeda,et al.  The roles of IFN gamma in protection against tumor development and cancer immunoediting. , 2002, Cytokine & growth factor reviews.

[69]  S. Coca,et al.  Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. , 2002, Lung cancer.

[70]  T. Lehnert,et al.  Malignancy after renal transplantation. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[71]  R. Vile Faculty Opinions recommendation of IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. , 2001 .

[72]  T. Taniguchi,et al.  Antiviral response by natural killer cells through TRAIL gene induction by IFN–α/β  , 2001, European journal of immunology.

[73]  Adelheid Cerwenka,et al.  Natural killer cells, viruses and cancer , 2001, Nature Reviews Immunology.

[74]  A. Hayday,et al.  Regulation of Cutaneous Malignancy by γδ T Cells , 2001, Science.

[75]  U. Heemann,et al.  Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer , 2001, British Journal of Cancer.

[76]  T. Eberlein,et al.  Loss of T-cell receptor-CD3zeta and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma. , 2001, Surgery.

[77]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[78]  J. Trapani,et al.  A fresh look at tumor immunosurveillance and immunotherapy , 2001, Nature Immunology.

[79]  C. Heldin,et al.  Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. , 2001, Cancer research.

[80]  O. Finn,et al.  Suppressed T-cell receptor zeta chain expression and cytokine production in pancreatic cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[81]  H. Kalthoff,et al.  Systemic and local immunosuppression in pancreatic cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[82]  T. Grogan,et al.  Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. , 2001, Blood.

[83]  H. Schreiber,et al.  Role of TGF‐β in immune‐evasion of cancer , 2001 .

[84]  H. Schreiber,et al.  Role of TGF-beta in immune-evasion of cancer. , 2001, Microscopy research and technique.

[85]  A. Hayday,et al.  Regulation of cutaneous malignancy by gammadelta T cells. , 2001, Science.

[86]  M. Smyth,et al.  Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells , 2001, Nature Medicine.

[87]  M. Smyth,et al.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. , 2001, Blood.

[88]  M. Smyth,et al.  NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. , 2001, International immunology.

[89]  Y. Tabira,et al.  Accelerated growth signals and low tumor-infiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma. , 2000, The Annals of thoracic surgery.

[90]  J. Trapani,et al.  Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma , 2000, The Journal of experimental medicine.

[91]  T. Blankenstein,et al.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. , 2000, Immunity.

[92]  T. Whiteside,et al.  Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. , 2000, Blood.

[93]  J. Trapani,et al.  Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.

[94]  S. Natsugoe,et al.  Prognostic value of intratumoral natural killer cells in gastric carcinoma , 2000, Cancer.

[95]  M. Lotze,et al.  IFN-α-Expressing Tumor Cells Enhance Generation and Promote Survival of Tumor-Specific CTLs , 2000, The Journal of Immunology.

[96]  H. Kolb,et al.  Cutting Edge: Heat Shock Protein 60 Is a Putative Endogenous Ligand of the Toll-Like Receptor-4 Complex1 , 2000, The Journal of Immunology.

[97]  M. Lotze,et al.  IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. , 2000, Journal of immunology.

[98]  X. He,et al.  Prostaglandin E2 selectively inhibits human CD4+ T cells secreting low amounts of both IL-2 and IL-4. , 1999, Journal of immunology.

[99]  T. Whiteside,et al.  Caspase-mediated Degradation of T-Cell Receptor z-Chain1 , 1999 .

[100]  P. Klenerman,et al.  Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[101]  T. Whiteside,et al.  Caspase-mediated degradation of T-cell receptor zeta-chain. , 1999, Cancer research.

[102]  D. Carbone,et al.  Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. , 1998, Blood.

[103]  R. Day,et al.  Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. , 1998, Cancer research.

[104]  C. Copie-Bergman,et al.  CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs. , 1998, The Journal of clinical investigation.

[105]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[106]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[107]  J. Sprent,et al.  Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. , 1998, Immunity.

[108]  D. Carbone,et al.  Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. , 1998, Journal of immunology.

[109]  R. Schreiber,et al.  Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[110]  B. Bonavida,et al.  The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent , 1997, Cancer Immunology, Immunotherapy.

[111]  I. Svane,et al.  MCA Sarcomas Induced in scid Mice are More Immunogenic than MCA Sarcomas Induced in Congenic, Immunocompetent Mice , 1997, Scandinavian journal of immunology.

[112]  R. Zinkernagel,et al.  Decreased tumor surveillance in perforin-deficient mice , 1996, The Journal of experimental medicine.

[113]  H. Ljunggren,et al.  Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice , 1996, European journal of immunology.

[114]  I. Svane,et al.  Methylcholanthrene‐induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression , 1996, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[115]  B. Griffith,et al.  Solid tumors after heart transplantation: lethality of lung cancer. , 1995, The Annals of thoracic surgery.

[116]  D. Taub,et al.  Human Interferon-inducible Protein 10 Is a Potent Inhibitor of Angiogenesis in Vivo , 1995 .

[117]  Eero Pukkala,et al.  Cancer risk after renal transplantation in the nordic countries, 1964–1986 , 1995, International journal of cancer.

[118]  R. Schreiber,et al.  Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. , 1994, Immunity.

[119]  P. Matzinger Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[120]  G. Sakamoto,et al.  Time dependency of the influence of prognostic factors on relapse in breast cancer , 1993, Cancer.

[121]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[122]  V. Stewart,et al.  RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement , 1992, Cell.

[123]  F. Belardelli,et al.  Antibody to mouse interferon alpha/beta abrogates resistance to the multiplication of Friend erythroleukemia cells in the livers of allogeneic mice , 1988, The Journal of experimental medicine.

[124]  R. Wattiaux,et al.  Subcellular localization of transglutaminase. Effect of collagen. , 1988, The Biochemical journal.

[125]  E. Coccia,et al.  Molecular mechanisms of action of interferons in the Friend virus-induced leukemia cell system. , 1987, Haematologica.

[126]  R. Herberman,et al.  Lymphocyte-mediated cytotoxicity. , 1987, Pediatric annals.

[127]  L. Sherman,et al.  The composition of the T cell receptor repertoire in nude mice. , 1987, Journal of immunology.

[128]  S. Ikehara,et al.  Functional T cells in athymic nude mice. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[129]  L. Thomas On immunosurveillance in human cancer. , 1982, The Yale journal of biology and medicine.

[130]  R. Herberman,et al.  Natural cell-mediated immunity. , 1978, Advances in cancer research.

[131]  G. Klein Immune surveillance--a powerful mechanism with a limited range. , 1976, National Cancer Institute monograph.

[132]  J. Rygaard,et al.  The mouse mutant nude does not develop spontaneous tumours. An argument against immunological surveillance. , 2009, Acta pathologica et microbiologica Scandinavica. Section B: Microbiology and immunology.

[133]  O. Stutman Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice , 1974, Science.

[134]  I. Gresser,et al.  Interferon and cell division. IX. Interferon-resistant L1210 cells: characteristics and origin. , 1974, Journal of the National Cancer Institute.

[135]  F. Burnet Immunological Surveillance in Neoplasia , 1971, Transplantation reviews.

[136]  Old Lj,et al.  Immunology of Experimental Tumors , 1964 .

[137]  L. Old,et al.  IMMUNOLOGY OF EXPERIMENTAL TUMORS. , 1964, Annual review of medicine.

[138]  R. Prehn,et al.  Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.

[139]  M BURNET,et al.  Cancer—A Biological Approach* , 1957, British medical journal.

[140]  M. Burnet Cancer—A Biological Approach , 1957, British medical journal.

[141]  E. Wills Enzyme inhibition by suramin and the measurement of the isoelectric points of some enzymes. , 1952, The Biochemical journal.

[142]  S. Jasko,et al.  Therapy , 1881, The American journal of dental science.